Strain Name:

B6SJL-Tg(Wnt1)1Hev/J

Stock Number:

002870

Order this mouse

Availability:

Cryopreserved - Ready for recovery

Use Restrictions Apply, see Terms of Use

Description

The genotypes of the animals provided may not reflect those discussed in the strain description or the mating scheme utilized by The Jackson Laboratory prior to cryopreservation. Please inquire for possible genotypes for this specific strain.

Strain Information

Type Mutant Strain; Transgenic;
Additional information on Genetically Engineered and Mutant Mice.
Visit our online Nomenclature tutorial.
Specieslaboratory mouse
 
Donating Investigator IMR Colony,   The Jackson Laboratory

Description
Mammary glands from virgin hemizygous females carrying the (Wnt1)1Hev transgene resemble hormonally-stimulated glands from pregnant mice. There was a marked increase in numbers of terminal branches and alveoli, producing a diffuse lobular hyperplasia. Parous transgenic females were unable to lactate. Hemizygous transgenic male glands, while less developed, also were hyperplastic. Adenocarcinomas developed between 3 and 7 months in females and more rarely in males. Occasional metastatic lesions were observed in females. Salivary adenocarcinomas were also occasionally observed in both males and females. Tumors arose stochastically, indicating additional events are required for neoplasia. Subsequent work with Wnt1 transgenic mice includes infection with MMTV to identify contributing oncogenes and mating to transgenic mice bearing other oncogenes.

Development
The construct contained an MMTV LTR about 1 kb upstream from a Wnt1 genomic clone, with SV40 splice and polyadenylation sites added at the 3' end. The construct was microinjected into (C57BL/6 X SJL)F1 fertilized eggs.

Control Information

  Control
   100012 B6SJLF1/J
 
  Considerations for Choosing Controls

Related Strains

Strains carrying   Tg(Wnt1)1Hev allele
002934   FVB.Cg-Tg(Wnt1)1Hev/J
View Strains carrying   Tg(Wnt1)1Hev     (1 strain)

View Strains carrying other alleles of Wnt1     (6 strains)

View Strains carrying other alleles of MMTV     (18 strains)

Phenotype

Phenotype Information

View Related Disease (OMIM) Terms

Related Disease (OMIM) Terms provided by MGI
- Characteristics of this human disease are associated with transgenes and other mutation types in the mouse.
Breast Cancer
- Potential model based on transgenic expression of a human gene that is associated with this disease. Phenotypic similarity to the human disease has not been tested.
Osteogenesis Imperfecta, Type Xv; OI15   (WNT1)
View Mammalian Phenotype Terms

Mammalian Phenotype Terms provided by MGI
      assigned by genotype

Tg(Wnt1)1Hev/0

        either: FVB/N or (involves: C57BL/6 * SJL)
  • endocrine/exocrine gland phenotype
  • abnormal mammary gland morphology
    • mammary glands in virgin females resemble hormonally-stimulated glands from pregnant mice   (MGI Ref ID J:28473)
    • abnormal branching of the mammary ductal tree
      • hemizygous transgenic females show a marked increase in the number of terminal branches   (MGI Ref ID J:28473)
    • abnormal mammary gland lobule morphology
      • hemizygous transgenic females display diffuse lobular hyperplasia   (MGI Ref ID J:28473)
      • mammary gland alveolar hyperplasia   (MGI Ref ID J:28473)
  • integument phenotype
  • abnormal mammary gland morphology
    • mammary glands in virgin females resemble hormonally-stimulated glands from pregnant mice   (MGI Ref ID J:28473)
    • abnormal branching of the mammary ductal tree
      • hemizygous transgenic females show a marked increase in the number of terminal branches   (MGI Ref ID J:28473)
    • abnormal mammary gland lobule morphology
      • hemizygous transgenic females display diffuse lobular hyperplasia   (MGI Ref ID J:28473)
      • mammary gland alveolar hyperplasia   (MGI Ref ID J:28473)

Tg(Wnt1)1Hev/0

        involves: C57BL/6 * SJL
  • tumorigenesis
  • increased mammary adenocarcinoma incidence
    • at 18 weeks   (MGI Ref ID J:61009)
  • endocrine/exocrine gland phenotype
  • mammary gland duct hyperplasia
    • at 18 weeks   (MGI Ref ID J:61009)
  • integument phenotype
  • mammary gland duct hyperplasia
    • at 18 weeks   (MGI Ref ID J:61009)

The following phenotype information is associated with a similar, but not exact match to this JAX® Mice strain.

Tg(Wnt1)1Hev/0

        involves: C57BL/6 * FVB * SJL
  • endocrine/exocrine gland phenotype
  • abnormal branching of the mammary ductal tree
    • mammary glands of virgin females have excessive ductal side branching resembling that of pregnant wild-type mice   (MGI Ref ID J:96305)
  • mammary gland hyperplasia
    • mammary glands of virgin females have extensive, dense hyperplasia   (MGI Ref ID J:96305)
  • tumorigenesis
  • increased mammary gland tumor incidence
    • develop mammary tumors   (MGI Ref ID J:96305)
  • integument phenotype
  • abnormal branching of the mammary ductal tree
    • mammary glands of virgin females have excessive ductal side branching resembling that of pregnant wild-type mice   (MGI Ref ID J:96305)
  • mammary gland hyperplasia
    • mammary glands of virgin females have extensive, dense hyperplasia   (MGI Ref ID J:96305)

Tg(Wnt1)1Hev/0

        involves: 129P2/OlaHsd * C57BL/6 * SJL
  • tumorigenesis
  • increased mammary adenocarcinoma incidence
    • both sexes develop lobuloalveolar adenocarcinomas   (MGI Ref ID J:54215)
    • tumor development or progression is not affected by pregnancies or ovariectomy   (MGI Ref ID J:54215)
  • endocrine/exocrine gland phenotype
  • mammary gland alveolar hyperplasia
    • lobuloalveolar hyperplasia in virgin females   (MGI Ref ID J:54215)
  • mammary gland duct hyperplasia
    • in virgin females   (MGI Ref ID J:54215)
  • mammary gland hyperplasia
    • at 10 weeks of age in virgin females   (MGI Ref ID J:54215)
    • at 6 months of age in virgin females, hyperplastic epithelium fills the entire inguinal fat pad   (MGI Ref ID J:54215)
    • males display epithelial hyperplasia that does not extend into the inguinal fat pad   (MGI Ref ID J:54215)
  • integument phenotype
  • mammary gland alveolar hyperplasia
    • lobuloalveolar hyperplasia in virgin females   (MGI Ref ID J:54215)
  • mammary gland duct hyperplasia
    • in virgin females   (MGI Ref ID J:54215)
  • mammary gland hyperplasia
    • at 10 weeks of age in virgin females   (MGI Ref ID J:54215)
    • at 6 months of age in virgin females, hyperplastic epithelium fills the entire inguinal fat pad   (MGI Ref ID J:54215)
    • males display epithelial hyperplasia that does not extend into the inguinal fat pad   (MGI Ref ID J:54215)
View Research Applications

Research Applications
This mouse can be used to support research in many areas including:

Cancer Research
Increased Tumor Incidence
      Mammary Gland Tumors

Genes & Alleles

Gene & Allele Information provided by MGI

 
Allele Symbol Tg(Wnt1)1Hev
Allele Name transgene insertion 1, Harold E Varmus
Allele Type Transgenic (Inserted expressed sequence)
Common Name(s) MMTV-Wnt-1; MMTV-Wnt1; MMTV-wnt; Wnt-1; line 303;
Mutation Made ByDr. Harold Varmus,   Memorial Sloan-Kettering Cancer Center
Strain of OriginC57BL/6 x SJL
Expressed Gene Wnt1, wingless-type MMTV integration site family, member 1, mouse, laboratory
Promoter MMTV, Mouse Mammary Tumor Virus, MMTV
Molecular Note Wnt1 is driven by the mouse mammary tumor virus (MMTV). The construct resembles alleles found in virus-induced tumors. [MGI Ref ID J:28473]
 
 

Genotyping

Genotyping Information

Genotyping Protocols

Tg(Wnt1)1Hev, Melt Curve Analysis
Tg(Wnt1)1Hev, Standard PCR


Helpful Links

Genotyping resources and troubleshooting

References

References provided by MGI

Selected Reference(s)

Tsukamoto AS; Grosschedl R; Guzman RC; Parslow T; Varmus HE. 1988. Expression of the int-1 gene in transgenic mice is associated with mammary gland hyperplasia and adenocarcinomas in male and female mice. Cell 55(4):619-25. [PubMed: 3180222]  [MGI Ref ID J:28473]

Additional References

Tg(Wnt1)1Hev related

Alexander CM; Reichsman F; Hinkes MT; Lincecum J; Becker KA; Cumberledge S; Bernfield M. 2000. Syndecan-1 is required for wnt-1-induced mammary tumorigenesis in mice Nat Genet 25(3):329-32. [PubMed: 10888884]  [MGI Ref ID J:63122]

Bai L; Rohrschneider LR. 2010. s-SHIP promoter expression marks activated stem cells in developing mouse mammary tissue. Genes Dev 24(17):1882-92. [PubMed: 20810647]  [MGI Ref ID J:163521]

Baker R; Kent CV; Silbermann RA; Hassell JA; Young LJ; Howe LR. 2010. Pea3 transcription factors and wnt1-induced mouse mammary neoplasia. PLoS One 5(1):e8854. [PubMed: 20107508]  [MGI Ref ID J:157624]

Balboni AL; Hutchinson JA; DeCastro AJ; Cherukuri P; Liby K; Sporn MB; Schwartz GN; Wells WA; Sempere LF; Yu PB; DiRenzo J. 2013. DeltaNp63alpha-mediated activation of bone morphogenetic protein signaling governs stem cell activity and plasticity in normal and malignant mammary epithelial cells. Cancer Res 73(2):1020-30. [PubMed: 23243027]  [MGI Ref ID J:194364]

Bocchinfuso WP; Hively WP; Couse JF; Varmus HE; Korach KS. 1999. A mouse mammary tumor virus-Wnt-1 transgene induces mammary gland hyperplasia and tumorigenesis in mice lacking estrogen receptor-alpha. Cancer Res 59(8):1869-76. [PubMed: 10213494]  [MGI Ref ID J:54215]

Brisken C; Heineman A; Chavarria T; Elenbaas B; Tan J; Dey SK; McMahon JA; McMahon AP; Weinberg RA. 2000. Essential function of Wnt-4 in mammary gland development downstream of progesterone signaling. Genes Dev 14(6):650-4. [PubMed: 10733525]  [MGI Ref ID J:61384]

Broccoli D; Godley LA; Donehower LA; Varmus HE; de Lange T. 1996. Telomerase activation in mouse mammary tumors: lack of detectable telomere shortening and evidence for regulation of telomerase RNA with cell proliferation. Mol Cell Biol 16(7):3765-72. [PubMed: 8668193]  [MGI Ref ID J:71575]

Bu W; Chen J; Morrison GD; Huang S; Creighton CJ; Huang J; Chamness GC; Hilsenbeck SG; Roop DR; Leavitt AD; Li Y. 2011. Keratin 6a marks mammary bipotential progenitor cells that can give rise to a unique tumor model resembling human normal-like breast cancer. Oncogene 30(43):4399-409. [PubMed: 21532625]  [MGI Ref ID J:178580]

Bulavin DV; Phillips C; Nannenga B; Timofeev O; Donehower LA; Anderson CW; Appella E; Fornace AJ Jr. 2004. Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK-mediated activation of the p16(Ink4a)-p19(Arf) pathway. Nat Genet 36(4):343-50. [PubMed: 14991053]  [MGI Ref ID J:121570]

Cao Y; Luo JL; Karin M. 2007. IkappaB kinase alpha kinase activity is required for self-renewal of ErbB2/Her2-transformed mammary tumor-initiating cells. Proc Natl Acad Sci U S A 104(40):15852-7. [PubMed: 17890319]  [MGI Ref ID J:125555]

Chen DY; Lee Y; Van Tine BA; Searleman AC; Westergard TD; Liu H; Tu HC; Takeda S; Dong Y; Piwnica-Worms DR; Oh KJ; Korsmeyer SJ; Hermone A; Gussio R; Shoemaker RH; Cheng EH; Hsieh JJ. 2012. A pharmacologic inhibitor of the protease Taspase1 effectively inhibits breast and brain tumor growth. Cancer Res 72(3):736-46. [PubMed: 22166309]  [MGI Ref ID J:181107]

Cho RW; Wang X; Diehn M; Shedden K; Chen GY; Sherlock G; Gurney A; Lewicki J; Clarke MF. 2008. Isolation and molecular characterization of cancer stem cells in MMTV-Wnt-1 murine breast tumors. Stem Cells 26(2):364-71. [PubMed: 17975224]  [MGI Ref ID J:144892]

Cleary AS; Leonard TL; Gestl SA; Gunther EJ. 2014. Tumour cell heterogeneity maintained by cooperating subclones in Wnt-driven mammary cancers. Nature 508(7494):113-7. [PubMed: 24695311]  [MGI Ref ID J:208879]

Coombs GS; Schmitt AA; Canning CA; Alok A; Low IC; Banerjee N; Kaur S; Utomo V; Jones CM; Pervaiz S; Toone EJ; Virshup DM. 2012. Modulation of Wnt/beta-catenin signaling and proliferation by a ferrous iron chelator with therapeutic efficacy in genetically engineered mouse models of cancer. Oncogene 31(2):213-25. [PubMed: 21666721]  [MGI Ref ID J:179415]

Donehower LA; Godley LA; Aldaz CM; Pyle R; Shi YP; Pinkel D; Gray J; Bradley A; Medina D; Varmus HE. 1995. Deficiency of p53 accelerates mammary tumorigenesis in Wnt-1 transgenic mice and promotes chromosomal instability. Genes Dev 9(7):882-95. [PubMed: 7705663]  [MGI Ref ID J:24407]

Dong J; Huang S; Caikovski M; Ji S; McGrath A; Custorio MG; Creighton CJ; Maliakkal P; Bogoslovskaia E; Du Z; Zhang X; Lewis MT; Sablitzky F; Brisken C; Li Y. 2011. ID4 regulates mammary gland development by suppressing p38MAPK activity. Development 138(23):5247-56. [PubMed: 22069192]  [MGI Ref ID J:178679]

Du Z; Podsypanina K; Huang S; McGrath A; Toneff MJ; Bogoslovskaia E; Zhang X; Moraes RC; Fluck M; Allred DC; Lewis MT; Varmus HE; Li Y. 2006. Introduction of oncogenes into mammary glands in vivo with an avian retroviral vector initiates and promotes carcinogenesis in mouse models. Proc Natl Acad Sci U S A 103(46):17396-401. [PubMed: 17090666]  [MGI Ref ID J:117125]

Glover CE; Gurley KE; Kim KH; Storer B; Fero ML; Kemp CJ. 2009. Endocrine dysfunction in p27Kip1 deficient mice and susceptibility to Wnt-1 driven breast cancer. Carcinogenesis 30(6):1058-63. [PubMed: 19380520]  [MGI Ref ID J:149486]

Herschkowitz JI; Simin K; Weigman VJ; Mikaelian I; Usary J; Hu Z; Rasmussen KE; Jones LP; Assefnia S; Chandrasekharan S; Backlund MG; Yin Y; Khramtsov AI; Bastein R; Quackenbush J; Glazer RI; Brown PH; Green JE; Kopelovich L; Furth PA; Palazzo JP; Olopade OI; Bernard PS; Churchill GA; Van Dyke T; Perou CM. 2007. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 8(5):R76. [PubMed: 17493263]  [MGI Ref ID J:160877]

Howe LR; Crawford HC; Subbaramaiah K; Hassell JA; Dannenberg AJ; Brown AM. 2001. PEA3 is up-regulated in response to Wnt1 and activates the expression of cyclooxygenase-2. J Biol Chem 276(23):20108-15. [PubMed: 11274170]  [MGI Ref ID J:210942]

Huang S; Li Y; Chen Y; Podsypanina K; Chamorro M; Olshen AB; Desai KV; Tann A; Petersen D; Green JE; Varmus HE. 2005. Changes in gene expression during the development of mammary tumors in MMTV-Wnt-1 transgenic mice. Genome Biol 6(10):R84. [PubMed: 16207355]  [MGI Ref ID J:103821]

Jones JM; Attardi L; Godley LA; Laucirica R; Medina D; Jacks T ; Varmus HE ; Donehower LA. 1997. Absence of p53 in a mouse mammary tumor model promotes tumor cell proliferation without affecting apoptosis. Cell Growth Differ 8(8):829-38. [PubMed: 9269892]  [MGI Ref ID J:43335]

Jones JM; Cui XS; Medina D; Donehower LA. 1999. Heterozygosity of p21WAF1/CIP1 enhances tumor cell proliferation and cyclin D1-associated kinase activity in a murine mammary cancer model. Cell Growth Differ 10(4):213-22. [PubMed: 10319991]  [MGI Ref ID J:54464]

Kapoun AM; Shackleford GM. 1997. Preferential activation of Fgf8 by proviral insertion in mammary tumors of Wnt1 transgenic mice. Oncogene 14(24):2985-9. [PubMed: 9205106]  [MGI Ref ID J:41162]

Kessenbrock K; Dijkgraaf GJ; Lawson DA; Littlepage LE; Shahi P; Pieper U; Werb Z. 2013. A role for matrix metalloproteinases in regulating mammary stem cell function via the Wnt signaling pathway. Cell Stem Cell 13(3):300-13. [PubMed: 23871604]  [MGI Ref ID J:201913]

Kim S; Goel S; Alexander CM. 2011. Differentiation generates paracrine cell pairs that maintain basaloid mouse mammary tumors: proof of concept. PLoS One 6(4):e19310. [PubMed: 21541292]  [MGI Ref ID J:172378]

Kim YC; Clark RJ; Ranheim EA; Alexander CM. 2008. Wnt1 expression induces short-range and long-range cell recruitments that modify mammary tumor development and are not induced by a cell-autonomous beta-catenin effector. Cancer Res 68(24):10145-53. [PubMed: 19074881]  [MGI Ref ID J:142240]

Kouros-Mehr H; Bechis SK; Slorach EM; Littlepage LE; Egeblad M; Ewald AJ; Pai SY; Ho IC; Werb Z. 2008. GATA-3 links tumor differentiation and dissemination in a luminal breast cancer model. Cancer Cell 13(2):141-52. [PubMed: 18242514]  [MGI Ref ID J:131913]

Kwan H; Pecenka V; Tsukamoto A; Parslow TG; Guzman R; Lin TP; Muller WJ; Lee FS; Leder P; Varmus HE. 1992. Transgenes expressing the Wnt-1 and int-2 proto-oncogenes cooperate during mammary carcinogenesis in doubly transgenic mice. Mol Cell Biol 12(1):147-54. [PubMed: 1530875]  [MGI Ref ID J:1811]

Lane TF; Leder P. 1997. Wnt-10b directs hypermorphic development and transformation in mammary glands of male and female mice. Oncogene 15(18):2133-44. [PubMed: 9393971]  [MGI Ref ID J:44244]

Lee CY; Lin Y; Bratman SV; Feng W; Kuo AH; Scheeren FA; Engreitz JM; Varma S; West RB; Diehn M. 2014. Neuregulin autocrine signaling promotes self-renewal of breast tumor-initiating cells by triggering HER2/HER3 activation. Cancer Res 74(1):341-52. [PubMed: 24177178]  [MGI Ref ID J:206603]

Li Y; Hively WP; Varmus HE. 2000. Use of MMTV-Wnt-1 transgenic mice for studying the genetic basis of breast cancer. Oncogene 19(8):1002-9. [PubMed: 10713683]  [MGI Ref ID J:61009]

Li Y; Podsypanina K; Liu X; Crane A; Tan LK; Parsons R; Varmus HE. 2001. Deficiency of Pten accelerates mammary oncogenesis in MMTV-Wnt-1 transgenic mice. BMC Mol Biol 2(1):2. [PubMed: 11178110]  [MGI Ref ID J:67497]

Li Y; Welm B; Podsypanina K; Huang S; Chamorro M; Zhang X; Rowlands T; Egeblad M; Cowin P; Werb Z; Tan LK; Rosen JM; Varmus HE. 2003. Evidence that transgenes encoding components of the Wnt signaling pathway preferentially induce mammary cancers from progenitor cells. Proc Natl Acad Sci U S A 100(26):15853-8. [PubMed: 14668450]  [MGI Ref ID J:87520]

Lin T; Meng L; Li Y; Tsai RY. 2010. Tumor-initiating function of nucleostemin-enriched mammary tumor cells. Cancer Res 70(22):9444-52. [PubMed: 21045149]  [MGI Ref ID J:166705]

Lin TP; Guzman RC; Osborn RC; Thordarson G; Nandi S. 1992. Role of endocrine, autocrine, and paracrine interactions in the development of mammary hyperplasia in Wnt-1 transgenic mice. Cancer Res 52(16):4413-9. [PubMed: 1386556]  [MGI Ref ID J:2062]

Lindvall C; Evans NC; Zylstra CR; Li Y; Alexander CM; Williams BO. 2006. The Wnt signaling receptor Lrp5 is required for mammary ductal stem cell activity and Wnt1-induced tumorigenesis. J Biol Chem 281(46):35081-7. [PubMed: 16973609]  [MGI Ref ID J:115934]

Lindvall C; Zylstra CR; Evans N; West RA; Dykema K; Furge KA; Williams BO. 2009. The Wnt co-receptor Lrp6 is required for normal mouse mammary gland development. PLoS One 4(6):e5813. [PubMed: 19503830]  [MGI Ref ID J:150203]

Liu BY; McDermott SP; Khwaja SS; Alexander CM. 2004. The transforming activity of Wnt effectors correlates with their ability to induce the accumulation of mammary progenitor cells. Proc Natl Acad Sci U S A 101(12):4158-63. [PubMed: 15020770]  [MGI Ref ID J:89233]

Liu Q; Guntuku S; Cui XS; Matsuoka S; Cortez D; Tamai K; Luo G; Carattini-Rivera S; DeMayo F; Bradley A; Donehower LA; Elledge SJ. 2000. Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Dev 14(12):1448-59. [PubMed: 10859164]  [MGI Ref ID J:62919]

MacArthur CA; Shankar DB; Shackleford GM. 1995. Fgf-8, activated by proviral insertion, cooperates with the Wnt-1 transgene in murine mammary tumorigenesis. J Virol 69(4):2501-7. [PubMed: 7884899]  [MGI Ref ID J:23751]

Marino S; Romelfanger C; Yokota Y; Nusse R. 2004. Wnt1 is epistatic to Id2 in inducing mammary hyperplasia, ductal side-branching, and tumors in the mouse. BMC Cancer 4(1):91. [PubMed: 15601467]  [MGI Ref ID J:96305]

Maruyama EO; Yu HM; Jiang M; Fu J; Hsu W. 2013. Gpr177 deficiency impairs mammary development and prohibits Wnt-induced tumorigenesis. PLoS One 8(2):e56644. [PubMed: 23457599]  [MGI Ref ID J:199398]

Mastroianni M; Kim S; Kim YC; Esch A; Wagner C; Alexander CM. 2010. Wnt signaling can substitute for estrogen to induce division of ERalpha-positive cells in a mouse mammary tumor model. Cancer Lett 289(1):23-31. [PubMed: 19665836]  [MGI Ref ID J:157204]

Mikaelian I; Blades N; Churchill GA; Fancher K; Knowles BB; Eppig JT; Sundberg JP. 2004. Proteotypic classification of spontaneous and transgenic mammary neoplasms. Breast Cancer Res 6(6):R668-79. [PubMed: 15535849]  [MGI Ref ID J:94093]

Montales MT; Melnyk SB; Simmen FA; Simmen RC. 2014. Maternal metabolic perturbations elicited by high-fat diet promote Wnt-1-induced mammary tumor risk in adult female offspring via long-term effects on mammary and systemic phenotypes. Carcinogenesis 35(9):2102-12. [PubMed: 24832086]  [MGI Ref ID J:212748]

Montales MT; Rahal OM; Kang J; Rogers TJ; Prior RL; Wu X; Simmen RC. 2012. Repression of mammosphere formation of human breast cancer cells by soy isoflavone genistein and blueberry polyphenolic acids suggests diet-mediated targeting of cancer stem-like/progenitor cells. Carcinogenesis 33(3):652-60. [PubMed: 22219179]  [MGI Ref ID J:181503]

Morishita A; Zaidi MR; Mitoro A; Sankarasharma D; Szabolcs M; Okada Y; D'Armiento J; Chada K. 2013. HMGA2 Is a Driver of Tumor Metastasis. Cancer Res 73(14):4289-99. [PubMed: 23722545]  [MGI Ref ID J:199102]

O'Hagan R; Chang S; Maser R; Mohan R; Artandi S; Chin L; DePinho R. 2002. Telomere dysfunction provokes regional amplification and deletion in cancer genomes. Cancer Cell 2(2):149-55. [PubMed: 12204535]  [MGI Ref ID J:78479]

Podsypanina K; Li Y; Varmus HE. 2004. Evolution of somatic mutations in mammary tumors in transgenic mice is influenced by the inherited genotype. BMC Med 2(1):24. [PubMed: 15198801]  [MGI Ref ID J:91649]

Pond AC; Herschkowitz JI; Schwertfeger KL; Welm B; Zhang Y; York B; Cardiff RD; Hilsenbeck S; Perou CM; Creighton CJ; Lloyd RE; Rosen JM. 2010. Fibroblast growth factor receptor signaling dramatically accelerates tumorigenesis and enhances oncoprotein translation in the mouse mammary tumor virus-Wnt-1 mouse model of breast cancer. Cancer Res 70(12):4868-79. [PubMed: 20501844]  [MGI Ref ID J:160915]

Proffitt KD; Madan B; Ke Z; Pendharkar V; Ding L; Lee MA; Hannoush RN; Virshup DM. 2013. Pharmacological inhibition of the Wnt acyltransferase PORCN prevents growth of WNT-driven mammary cancer. Cancer Res 73(2):502-7. [PubMed: 23188502]  [MGI Ref ID J:194379]

Rahal OM; Pabona JM; Kelly T; Huang Y; Hennings LJ; Prior RL; Al-Dwairi A; Simmen FA; Simmen RC. 2013. Suppression of Wnt1-induced mammary tumor growth and lower serum insulin in offspring exposed to maternal blueberry diet suggest early dietary influence on developmental programming. Carcinogenesis 34(2):464-74. [PubMed: 23144318]  [MGI Ref ID J:194111]

Reddy HK; Mettus RV; Rane SG; Grana X; Litvin J; Reddy EP. 2005. Cyclin-dependent kinase 4 expression is essential for neu-induced breast tumorigenesis. Cancer Res 65(22):10174-8. [PubMed: 16288002]  [MGI Ref ID J:103411]

Schroeder JA; Adriance MC; Thompson MC; Camenisch TD; Gendler SJ. 2003. MUC1 alters beta-catenin-dependent tumor formation and promotes cellular invasion. Oncogene 22(9):1324-32. [PubMed: 12618757]  [MGI Ref ID J:82470]

Shackleford GM; MacArthur CA; Kwan HC; Varmus HE. 1993. Mouse mammary tumor virus infection accelerates mammary carcinogenesis in Wnt-1 transgenic mice by insertional activation of int-2/Fgf-3 and hst/Fgf-4. Proc Natl Acad Sci U S A 90(2):740-4. [PubMed: 8380647]  [MGI Ref ID J:3728]

Shekhar MP; Gerard B; Pauley RJ; Williams BO; Tait L. 2008. Rad6B is a positive regulator of beta-catenin stabilization. Cancer Res 68(6):1741-50. [PubMed: 18339854]  [MGI Ref ID J:150916]

Sun M; Gomes S; Chen P; Frankenberger CA; Sankarasharma D; Chung CH; Chada KK; Rosner MR. 2014. RKIP and HMGA2 regulate breast tumor survival and metastasis through lysyl oxidase and syndecan-2. Oncogene 33(27):3528-37. [PubMed: 23975428]  [MGI Ref ID J:212607]

Sun M; Song CX; Huang H; Frankenberger CA; Sankarasharma D; Gomes S; Chen P; Chen J; Chada KK; He C; Rosner MR. 2013. HMGA2/TET1/HOXA9 signaling pathway regulates breast cancer growth and metastasis. Proc Natl Acad Sci U S A 110(24):9920-5. [PubMed: 23716660]  [MGI Ref ID J:197399]

Teissedre B ; Pinderhughes A ; Incassati A ; Hatsell SJ ; Hiremath M ; Cowin P. 2009. MMTV-Wnt1 and -DeltaN89beta-catenin induce canonical signaling in distinct progenitors and differentially activate Hedgehog signaling within mammary tumors. PLoS ONE 4(2):e4537. [PubMed: 19225568]  [MGI Ref ID J:146601]

Vaillant F; Asselin-Labat ML; Shackleton M; Forrest NC; Lindeman GJ; Visvader JE. 2008. The mammary progenitor marker CD61/beta3 integrin identifies cancer stem cells in mouse models of mammary tumorigenesis. Cancer Res 68(19):7711-7. [PubMed: 18829523]  [MGI Ref ID J:141826]

Watanabe K; Fallahi M; Dai X. 2014. Chromatin effector Pygo2 regulates mammary tumor initiation and heterogeneity in MMTV-Wnt1 mice. Oncogene 33(5):632-42. [PubMed: 23334328]  [MGI Ref ID J:205176]

Watanabe K; Villarreal-Ponce A; Sun P; Salmans ML; Fallahi M; Andersen B; Dai X. 2014. Mammary morphogenesis and regeneration require the inhibition of EMT at terminal end buds by Ovol2 transcriptional repressor. Dev Cell 29(1):59-74. [PubMed: 24735879]  [MGI Ref ID J:211311]

Wu Y; Wang Y; Yang XH; Kang T; Zhao Y; Wang C; Evers BM; Zhou BP. 2013. The deubiquitinase USP28 stabilizes LSD1 and confers stem-cell-like traits to breast cancer cells. Cell Rep 5(1):224-36. [PubMed: 24075993]  [MGI Ref ID J:203784]

Yu Q; Geng Y; Sicinski P. 2001. Specific protection against breast cancers by cyclin D1 ablation. Nature 411(6841):1017-21. [PubMed: 11429595]  [MGI Ref ID J:70276]

Yue W; Santen RJ; Wang JP; Li Y; Verderame MF; Bocchinfuso WP; Korach KS; Devanesan P; Todorovic R; Rogan EG; Cavalieri EL. 2003. Genotoxic metabolites of estradiol in breast: potential mechanism of estradiol induced carcinogenesis. J Steroid Biochem Mol Biol 86(3-5):477-86. [PubMed: 14623547]  [MGI Ref ID J:86738]

Zhang X; Podsypanina K; Huang S; Mohsin SK; Chamness GC; Hatsell S; Cowin P; Schiff R; Li Y. 2005. Estrogen receptor positivity in mammary tumors of Wnt-1 transgenic mice is influenced by collaborating oncogenic mutations. Oncogene 24(26):4220-31. [PubMed: 15824740]  [MGI Ref ID J:99546]

Zhao H; Cui Y; Dupont J; Sun H; Hennighausen L; Yakar S. 2005. Overexpression of the tumor suppressor gene phosphatase and tensin homologue partially inhibits wnt-1-induced mammary tumorigenesis. Cancer Res 65(15):6864-73. [PubMed: 16061670]  [MGI Ref ID J:100768]

Health & husbandry

The genotypes of the animals provided may not reflect those discussed in the strain description or the mating scheme utilized by The Jackson Laboratory prior to cryopreservation. Please inquire for possible genotypes for this specific strain.

Health & Colony Maintenance Information

Animal Health Reports

Production of mice from cryopreserved embryos or sperm occurs in a maximum barrier room, G200.

Colony Maintenance

Breeding & HusbandryHemizygotes are fertile, but hemizygous females do not lactate. When maintaining a live colony, transgenic males can be mated to B6SJLF1/J (JR#100012) females. Expected coat color from breeding:Black, White Bellied Agouti, Light Gray and Tan w/ pink eyes.

Pricing and Purchasing

Pricing, Supply Level & Notes, Controls


Pricing for USA, Canada and Mexico shipping destinations View International Pricing

Cryopreserved

Cryopreserved Mice - Ready for Recovery

Price (US dollars $)
Cryorecovery* $2140.00
Animals Provided

At least two mice that carry the mutation (if it is a mutant strain) will be provided. Their genotypes may not reflect those discussed in the strain description. Please inquire for possible genotypes and see additional details below.

Standard Supply

Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.

Supply Notes

  • Cryorecovery - Standard.
    Progeny testing is not required.

    The average number of mice provided from recovery of our cryopreserved strains is 10. The total number of animals provided, their gender and genotype will vary. We will fulfill your order by providing at least two pair of mice, at least one animal of each pair carrying the mutation of interest. Please inquire if larger numbers of animals with specific genotype and genders are needed. Animals typically ship between 10 and 14 weeks from the date of your order. If a second cryorecovery is needed in order to provide the minimum number of animals, animals will ship within 25 weeks. IMPORTANT NOTE: The genotypes of animals provided may not reflect the mating scheme utilized by The Jackson Laboratory prior to cryopreservation, or that discussed in the strain description. Please inquire about possible genotypes which will be recovered for this specific strain. The Jackson Laboratory cannot guarantee the reproductive success of mice shipped to your facility. If the mice are lost after the first three days (post-arrival) or do not produce progeny at your facility, a new order and fee will be necessary.

    Cryorecovery to establish a Dedicated Supply for greater quantities of mice. Mice recovered can be used to establish a dedicated colony to contractually supply you mice according to your requirements. Price by quotation. For more information on Dedicated Supply, please contact JAX® Services, Tel: 1-800-422-6423 (from U.S.A., Canada or Puerto Rico only) or 1-207-288-5845 (from any location).

Pricing for International shipping destinations View USA Canada and Mexico Pricing

Cryopreserved

Cryopreserved Mice - Ready for Recovery

Price (US dollars $)
Cryorecovery* $2782.00
Animals Provided

At least two mice that carry the mutation (if it is a mutant strain) will be provided. Their genotypes may not reflect those discussed in the strain description. Please inquire for possible genotypes and see additional details below.

Standard Supply

Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.

Supply Notes

  • Cryorecovery - Standard.
    Progeny testing is not required.

    The average number of mice provided from recovery of our cryopreserved strains is 10. The total number of animals provided, their gender and genotype will vary. We will fulfill your order by providing at least two pair of mice, at least one animal of each pair carrying the mutation of interest. Please inquire if larger numbers of animals with specific genotype and genders are needed. Animals typically ship between 10 and 14 weeks from the date of your order. If a second cryorecovery is needed in order to provide the minimum number of animals, animals will ship within 25 weeks. IMPORTANT NOTE: The genotypes of animals provided may not reflect the mating scheme utilized by The Jackson Laboratory prior to cryopreservation, or that discussed in the strain description. Please inquire about possible genotypes which will be recovered for this specific strain. The Jackson Laboratory cannot guarantee the reproductive success of mice shipped to your facility. If the mice are lost after the first three days (post-arrival) or do not produce progeny at your facility, a new order and fee will be necessary.

    Cryorecovery to establish a Dedicated Supply for greater quantities of mice. Mice recovered can be used to establish a dedicated colony to contractually supply you mice according to your requirements. Price by quotation. For more information on Dedicated Supply, please contact JAX® Services, Tel: 1-800-422-6423 (from U.S.A., Canada or Puerto Rico only) or 1-207-288-5845 (from any location).

View USA Canada and Mexico Pricing View International Pricing

Standard Supply

Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.

Control Information

  Control
   100012 B6SJLF1/J
 
  Considerations for Choosing Controls
  Control Pricing Information for Genetically Engineered Mutant Strains.
 

Payment Terms and Conditions

Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.


See Terms of Use tab for General Terms and Conditions


The Jackson Laboratory's Genotype Promise

The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project.
Ordering Information
JAX® Mice
Surgical and Preconditioning Services
JAX® Services
Customer Services and Support
Tel: 1-800-422-6423 or 1-207-288-5845
Fax: 1-207-288-6150
Technical Support Email Form

Terms of Use

Terms of Use


General Terms and Conditions


For Licensing and Use Restrictions view the link(s) below:
- Notice to customers in Canada.

Contact information

General inquiries regarding Terms of Use

Contracts Administration

phone:207-288-6470

JAX® Mice, Products & Services Conditions of Use

"MICE" means mouse strains, their progeny derived by inbreeding or crossbreeding, unmodified derivatives from mouse strains or their progeny supplied by The Jackson Laboratory ("JACKSON"). "PRODUCTS" means biological materials supplied by JACKSON, and their derivatives. "RECIPIENT" means each recipient of MICE, PRODUCTS, or services provided by JACKSON including each institution, its employees and other researchers under its control. MICE or PRODUCTS shall not be: (i) used for any purpose other than the internal research, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services. Acceptance of MICE or PRODUCTS from JACKSON shall be deemed as agreement by RECIPIENT to these conditions, and departure from these conditions requires JACKSON's prior written authorization.

No Warranty

MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.

In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of mice, products or services, JACKSON will, at its option, provide credit or replacement for the mice or product received or the services provided.

No Liability

In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS or services from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.

MICE and PRODUCTS are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.

The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or services. In addition, special terms and conditions of sale of certain MICE, PRODUCTS or services may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and services by JACKSON, and by its licensees and distributors.

Acceptance of delivery of MICE, PRODUCTS or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or services by JACKSON.


(6.8)